Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAIN-3
2024-516205-23-00Phase 2Authorised
- Sponsor
- Borstkanker Onderzoek Groep
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of trastuzumab, pertuzumab, trastuzumab emtansine, paclitaxel and carboplatin in breast cancer, sponsored by Borstkanker Onderzoek Groep. Primary endpoint: Three-year event-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516205-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516205-23-00.